Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:VTYX 23 October 2025 - 4 March 2026

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly shares fell 1% Tuesday to $1,007.73, extending losses ahead of an FDA decision on its oral obesity pill expected in April. Ventyx Biosciences shareholders approved a merger with Lilly, with Nasdaq set to halt Ventyx stock after hours Tuesday and the deal expected to close before Wednesday’s open. The FDA issued warning letters to 30 telehealth firms over ads for compounded weight-loss drugs.
4 March 2026
···
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Ventyx Biosciences shares surged about 85% in after-hours trading Oct. 22, closing at $7.15 after positive Phase 2 trial results for its NLRP3 inhibitor. The drug showed an 80% drop in hsCRP, a key inflammation marker, in obese patients with heart risk factors. VTX3232 was well tolerated and did not cause weight loss. Wall Street analysts set average 12-month price targets near $7.50, with some as high as $21.
23 October 2025
·

Stock Market Today

  • U.S. Stocks Dip as Global Markets Stabilize Following Oil Price Decline
    March 20, 2026, 10:12 AM EDT. U.S. stocks slipped on Thursday amid a slight easing in oil prices, which contributed to steadier markets worldwide. The decline in oil, a key commodity influencing economic sentiment, helped temper volatility in international exchanges. Investors demonstrated cautious optimism as they navigated geopolitical and economic uncertainties. The modest oil price retreat eased inflationary concerns, supporting a more balanced trading environment globally. This mixed performance reflects ongoing adjustments in response to energy price fluctuations and broader market trends.
Go toTop